+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Evidence for higher success rates and successful treatment earlier in Graves' disease with higher radioactive iodine doses

Evidence for higher success rates and successful treatment earlier in Graves' disease with higher radioactive iodine doses

Thyroid 22(10): 991-995

Graves' disease is commonly treated with curative intent using radioactive iodine (RAI). While higher doses have been shown to increase success rates, more evidence is needed. Further, very few studies assess the time to treatment success without the need for antithyroid drugs after a single dose of RAI within the first year post-dose, despite earlier success being an important treatment objective. We aimed to evaluate the outcome of different RAI doses in terms of success rates and time to achieve this success (eu- or hypothyroidism). We hypothesized that higher doses would not only increase success rates, but bring about successful treatment earlier. We retrospectively analyzed the medical records of all patients diagnosed with Graves' disease between 1994 and 2009. Details of RAI treatment and outcomes thereof were documented. In our analysis, we divided the patients who received RAI treatment into three groups according to the dose received: I (≤15 mCi); II (16-20 mCi); III (≥21 mCi). There were 498 patients diagnosed with Graves' disease. However, 105 were either lost to follow-up or still undergoing treatment. Of the remaining 393, there were 258 who received RAI treatment. The average initial dose was 21.42±6.5 mCi and overall success rate was 86%. Success rates were 74%, 85%, and 89% (p<0.05), while average time to successful treatment was 8.1, 4.6, and 2.9 months, respectively (p<0.001), for groups I, II, and III. When 20 mCi was given empirically, 85% obtained successful treatment; most of these within 3 months (mean 3.9; mode and median 3 months). This study provides additional evidence that success post-treatment correlates with administered dose and shows clearly, for the first time, that successful treatment is achieved earlier with higher doses. This knowledge is relevant to all clinicians managing Graves' disease as it can be taken into consideration when discussing treatment plans with patients.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 053094599

Download citation: RISBibTeXText

PMID: 22953990

DOI: 10.1089/thy.2011.0362

Related references

Treatment with propylthiouracil before radioactive iodine therapy is associated with a higher treatment failure rate than therapy with radioactive iodine alone in Graves' disease. Thyroid 5(4): 243-247, 1995

Graves' disease and atrial fibrillation: the case for even higher doses of therapeutic iodine-131. British Medical Journal 289(6442): 399-400, 1984

Higher frequency of screening TSH above 5 mIU/l in infants likely exposed to higher doses of iodine-containing skin antiseptic: implications for assessment of iodine sufficiency. Journal of Pediatric Endocrinology & Metabolism 22(4): 335-338, 2009

Sa1853 Asians With Hepatocellular Carcinoma (HCC) Have Earlier Staged Disease At Diagnosis and Higher Treatment Rates Whereas Blacks With HCC Have More Advanced Disease at Diagnosis and Lower Treatment Rates. Gastroenterology 148(4): S-1024-S-1025, 2015

Higher volume endovascular stroke centers have faster times to treatment, higher reperfusion rates and higher rates of good clinical outcomes. Journal of Neurointerventional Surgery 5(4): 294-297, 2014

Thyroid Isthmus Length and Iodine Turnover as Predictors of Successful Radioactive Iodine Therapy in Patients with Graves' Disease. International Journal of Endocrinology 2017: 7354673-7354673, 2018

Higher body weight and distant metastasis are associated with higher radiation exposure to the household environment from patients with thyroid cancer after radioactive iodine therapy. Medicine 96(35): E7942-E7942, 2017

Do higher doses of carbimazole improve remission in Graves' disease?. Qjm 89(5): 381-385, 1996

Accuracy considerations when using early (four- or six-hour) radioactive iodine uptake to predict twenty-four-hour values for radioactive iodine dosage in the treatment of Graves' disease. Thyroid 10(9): 779-787, 2000

Evidence that rates of advancement of long-distance passerine migrant arrival in the UK have been higher among earlier-arriving species. Ringing & Migration 27(1): 60-63, 2012

Radioactive Iodine As An Indicator In Thyroid Physiology. V. The Use Of Radioactive Iodine In The Differential Diagnosis Of Two Types Of Graves' Disease. Journal of Clinical Investigation 21(1): 31-32, 1942

Radioactive iodine in the treatment of Graves' disease. Saudi Medical Journal 23(9): 1049-1053, 2002

The use of radioactive iodine in the treatment of Graves disease. California Medicine 70(4): 235-239, 1949

Treatment of Graves' disease with radioactive iodine. Medical Clinics of North America 32: 3-17, 1948

Radioactive iodine in the study of thyroid physiology; the use of radioactive iodine therapy in Graves' disease. Western Journal of Surgery, Obstetrics, and Gynecology 54(12): 474-486, 2011